Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several li...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aort.aort_30_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850053372685582336 |
|---|---|
| author | Sreedhar Jayakrishnan Cherulil Kesavan Melarcode Ramanan Sudeep Vaniyath |
| author_facet | Sreedhar Jayakrishnan Cherulil Kesavan Melarcode Ramanan Sudeep Vaniyath |
| author_sort | Sreedhar Jayakrishnan Cherulil |
| collection | DOAJ |
| description | Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several lines of treatment is an often-encountered clinical scenario, here we would like to highlight the use of Daratumumab a novel anti CD 38 monoclonal antibody to treat post-transplant AIC. We report on the use of Daratumumab in combination with the conventional treatment with Rituximab and corticosteroids in a case of severe life threatening AIHA in a one-year-old child, who was suffering from T-B-NK SCID, and had undergone post haploidentical stem cell transplantation. |
| format | Article |
| id | doaj-art-ac13b77288fb4e6d85793201b1101317 |
| institution | DOAJ |
| issn | 2772-8382 2772-8390 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Oncology Research and Therapy |
| spelling | doaj-art-ac13b77288fb4e6d85793201b11013172025-08-20T02:52:34ZengWolters Kluwer Medknow PublicationsAnnals of Oncology Research and Therapy2772-83822772-83902025-01-0151666810.4103/aort.aort_30_24Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obviousSreedhar Jayakrishnan CherulilKesavan Melarcode RamananSudeep VaniyathAutoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several lines of treatment is an often-encountered clinical scenario, here we would like to highlight the use of Daratumumab a novel anti CD 38 monoclonal antibody to treat post-transplant AIC. We report on the use of Daratumumab in combination with the conventional treatment with Rituximab and corticosteroids in a case of severe life threatening AIHA in a one-year-old child, who was suffering from T-B-NK SCID, and had undergone post haploidentical stem cell transplantation.https://journals.lww.com/10.4103/aort.aort_30_24autoimmune cytopeniadaratumumabposthematopoietic stem cell transplant complicationsposttransplant cytopenia |
| spellingShingle | Sreedhar Jayakrishnan Cherulil Kesavan Melarcode Ramanan Sudeep Vaniyath Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious Annals of Oncology Research and Therapy autoimmune cytopenia daratumumab posthematopoietic stem cell transplant complications posttransplant cytopenia |
| title | Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious |
| title_full | Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious |
| title_fullStr | Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious |
| title_full_unstemmed | Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious |
| title_short | Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious |
| title_sort | daratumumab for refractory posttransplant autoimmune hemolytic anemia an option beyond the obvious |
| topic | autoimmune cytopenia daratumumab posthematopoietic stem cell transplant complications posttransplant cytopenia |
| url | https://journals.lww.com/10.4103/aort.aort_30_24 |
| work_keys_str_mv | AT sreedharjayakrishnancherulil daratumumabforrefractoryposttransplantautoimmunehemolyticanemiaanoptionbeyondtheobvious AT kesavanmelarcoderamanan daratumumabforrefractoryposttransplantautoimmunehemolyticanemiaanoptionbeyondtheobvious AT sudeepvaniyath daratumumabforrefractoryposttransplantautoimmunehemolyticanemiaanoptionbeyondtheobvious |